Stock Analiz

Collegium Pharmaceutical, Inc. COLL

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$25.32Market cap $787M
Open the interactive analysis →

Collegium Pharmaceutical, Inc. (COLL) is a healthcare company listed in the US with a market value of about $787M. In the twelve months to September 30, 2026 it had revenue of $815M and net income of $38M, a net margin of 4.7%.

Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is value (5/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 23.2, a price to free cash flow of 2.3, 5-year revenue growth of 20% a year, a 5-year average ROIC of 33%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 182% above the current price.

About Collegium Pharmaceutical

Collegium Pharmaceutical is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $2M in 2016 to $781M in 2025, growth of about 97.5% a year. It was profitable in 5 of the last 10 years in our data. Its share count rose by 17% over three years (dilution for shareholders).

Score: 3.2 / 5

Value5/5
Future growth4/5
Track record4/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Checks not passed

  • Profit margin improving
  • Profitable 5 years in a row
  • Interest covered more than 5 times
  • Liabilities below 60% of assets
  • Pays a dividend
  • Share count down over 3 years (buybacks)
  • 20% to 100% of free cash flow returned to shareholders
  • Dividend 3 years in a row

Valuation

P/E (TTM)23.2
Forward P/E3.6
P/FCF2.3
P/S1.0
P/B2.7
EV/EBITDA1.8
PEG1.30
Dividend yield0.00%
FCF yield42.7%
Shareholder yield3.2%
Intrinsic value vs. price+182%

Growth and quality

Revenue growth (1 yr)23.6%
Revenue growth (5 yrs, per year)20.3%
EPS growth (5 yrs, per year)17.9%
FCF growth (3 yrs, per year)38.8%
Net margin (5-yr avg.)9.6%
ROIC (5-yr avg.)32.7%
Profitable years (of last 10)5
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$815M$781M$631M$567M$464M$277M$310M$297M$280M$28M$2M
Net income$38M$63M$69M$48M-$25M$72M$27M-$23M-$39M-$75M-$94M
Free cash flow$336M$328M$203M$274M$123M$102M$88M$21M$164M-$68M-$76M
EPS (diluted)$1.09$1.73$1.86$1.29$-0.74$1.86$0.76$-0.68$-1.19$-2.47$-3.88
Net margin4.7%8.1%11.0%8.5%-5.4%25.8%8.6%-7.7%-14.0%-262.9%-5504.1%
ROIC—39.7%50.6%52.4%14.2%6.6%27.9%-21.8%-15.8%-57.3%-53.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $44.00, 74% above the current price; targets range from $28.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $7.46 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Collegium Pharmaceutical’s P/E ratio?

About 23.2, based on the last twelve months of diluted earnings per share (forward P/E about 3.6).

Is Collegium Pharmaceutical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 182% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Collegium Pharmaceutical pay a dividend?

Not currently.

Is Collegium Pharmaceutical a good stock to buy?

We do not give buy or sell advice. Collegium Pharmaceutical scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.